Pluristem Therapeutic (NASDAQ: PSTI - News), the Israel-based bio-therapeutics firm, is up 13% today after National Securities initiated coverage of the maker of cell therapy products with a "buy" rating. National Securities is bullish on Pluristem's cell delivery and homing capabilities and sees a significant catalyst in a pending trial with European and U.S. regulators. Volume in Pluristem is almost eight times the daily average usually seen at this point in the trading day.

http://finance.yahoo.com/q/ud?s=PSTIhttp://finance.yahoo.com/q/ud?s=PSTI

http://finance.yahoo.com/news/Pluristem-Shoots-Higher-On-indie-2887852022.html?x=0&.v=1